-- Conference Call Scheduled for Today at 8:30 a.m. ET -- DUBLIN, April 2, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461,...
from PR Newswire: //https://ift.tt/2EcQGBb
No comments:
Post a Comment